Program
Immunoglobulins, Intravenous
Also written as “NPB-01”, “TAK-881” and “IVIG”.
Its studies are mostly in Primary Immunodeficiency Diseases · Purpura, Thrombocytopenic, Idiopathic · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Immunologic Deficiency Syndromes · Myasthenia Gravis, led by 18 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 203 open or running | phase 4since Apr 12, 2017 | Sep 8, 2005 | May 16, 2028phase 3 · NCT06076642 |
| Grifols | 172 open or running | phase 4since Oct 24, 2011 | Sep 13, 2005 | Dec 31, 2027phase 3 · NCT07540221 |
| Nihon Pharmaceutical | 80 open or running | phase 3since Jul 27, 2011 | Dec 11, 2008 | none ahead |
| Octapharma | 61 open or running | phase 3since Nov 11, 2009 | Nov 11, 2009 | Nov 2026phase 3 · NCT04640142 |
| CSL | 51 open or running | phase 3since Oct 12, 2011 | Oct 12, 2011 | May 6, 2029phase 2 · NCT07048262 |
| Kedrion | 53 open or running | phase 3since Apr 16, 2012 | Apr 16, 2012 | Dec 2026phase 3 · NCT07059000 |
| Japan Blood Products Organization | 40 open or running | phase 3since Jun 8, 2006 | Jun 8, 2006 | none ahead |
| GC Biopharma | 31 open or running | phase 3since Jul 26, 2011 | Jul 26, 2011 | none ahead |
| Prothya Biosolutions | 30 open or running | phase 4since Aug 29, 2007 | Aug 29, 2007 | none ahead |
| Azidus Brasil | 22 open or running | phase 3since Sep 19, 2023 | Sep 19, 2023 | Sep 2028phase 3 · NCT06150833 |
| benesis-corporation | 20 open or running | phase 3since Jul 3, 2006 | Jul 3, 2006 | none ahead |
| biopharma-plasma-llc | 20 open or running | phase 3since Jul 15, 2020 | Jul 15, 2020 | none ahead |
| AstraZeneca | 10 open or running | phase 4since Aug 23, 2023 | Aug 23, 2023 | none ahead |
| dobri-kiprov | 11 open or running | phase 3since Jul 17, 2024 | Jul 17, 2024 | none ahead |
| evolve-biologics | 10 open or running | phase 3since Jul 21, 2017 | Jul 21, 2017 | none ahead |
| gammacan | 10 open or running | phase 2since Feb 19, 2006 | Feb 19, 2006 | none ahead |
| immunoe-research-centers | 10 open or running | phase 4since Nov 14, 2017 | Nov 14, 2017 | none ahead |
| isaac-melamed | 10 open or running | phase 4since Jul 21, 2014 | Jul 21, 2014 | none ahead |
Also a collaborator on its studies: Takeda Development Center Americas, Baxalta Innovations GmbH, now part of Shire, Parexel, Premier Research Group and TFS Trial Form Support.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 47 studies since Oct 6, 2010.
- Sep 19, 2023Azidus Brasil’s first study: phase 3 study in Primary Immunodeficiency DiseasesNew to Azidus BrasilAzidus Brasil · NCT06089122 · 50 planned
- Oct 4, 2023Phase 3 study in Primary Immunodeficiency DiseasesTakeda · NCT06076642 · 53 enrolled · United States, Czechia, Denmark and more
- Nov 21, 2023Phase 3 study in Primary Immunodeficiency DiseasesAzidus Brasil · NCT06150833 · 50 planned
- Jul 17, 2024dobri-kiprov’s first study: phase 3 study in AgingNew to dobri-kiprovdobri-kiprov · NCT06534450 · 40 enrolled · United States
- Dec 19, 2024Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingTakeda · NCT06747351 · 59 planned · United States, Argentina, Czechia and more
- Mar 20, 2025Phase 1 study in Healthy VolunteersTakeda · NCT06895967 · 30 enrolled · United States
- Apr 11, 2025Phase 1 study in Healthy VolunteersTakeda · NCT06935266 · 64 enrolled · United States
- May 13, 2025Phase 3 study in Multiple MyelomaTakeda · NCT06980480 · 183 planned · United States, Australia, Austria and more
- Jun 18, 2025Phase 3 study in Purpura, Thrombocytopenic, IdiopathicKedrion · NCT07059000 · 40 planned · United States, Czechia, Germany and more
- Jun 24, 2025Phase 2 study in InflammationCSL · NCT07048262 · 180 planned · Australia, Japan
- Apr 9, 20262 phase 3 studiesGrifols · NCT07540221, NCT07582432
- Apr 17, 2026Phase 3 study in Stiff-Person SyndromeKedrion · NCT07552987 · 38 planned
- Oct 19, 2026Primary completion moved from 2028-02-28 to 2029-05-06Date moved laterphase 2 · +14 months · NCT07048262
- Nov 9, 2026Primary completion moved from 2026-09 to 2026-11Date moved laterphase 3 · +2 months · NCT04640142
Ahead
- Nov 2026Primary completion: phase 3 study in Primary Immunodeficiency DiseasesOctapharma · NCT04640142
- Dec 2026Primary completion: phase 3 study in Purpura, Thrombocytopenic, IdiopathicKedrion · NCT07059000
- Dec 2026Primary completion: phase 3 study in Primary Immunodeficiency DiseasesKedrion · NCT04944979
- Dec 31, 2027Primary completion: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingGrifols · NCT07540221
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The newest 60 of 83 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07552987Stiff-Person Syndrome | 3 | Not yet recruiting | Kedrion | Jan 2028 | 38 |
| NCT07582432Leukemia, Lymphocytic, Chronic, B-Cell · United States | 3 | Recruiting | Grifols | Aug 31, 2028 | 49 |
| NCT07540221Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Czechia, Poland and more | 3 | Recruiting | Grifols | Dec 31, 2027 | 40 |
| NCT07048262Inflammation · Australia, Japan | 2 | Recruiting | CSL | May 6, 2029 | 180 |
| NCT07059000Purpura, Thrombocytopenic, Idiopathic · United States, Czechia, Germany and more | 3 | Recruiting | Kedrion | Dec 2026 | 40 |
| NCT06980480Multiple Myeloma · United States, Australia, Austria and more | 3 | Recruiting | Takeda | Sep 11, 2028 | 183 |
| NCT06935266Healthy Volunteers · United States | 1 | Completed | Takeda | Sep 27, 2025 | 64 |
| NCT06895967Healthy Volunteers · United States | 1 | Completed | Takeda | Jul 24, 2025 | 30 |
| NCT06747351Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Czechia and more | 3 | Recruiting | Takeda | Jun 25, 2028 | 59 |
| NCT06534450Aging · United States | 3 | Active, not recruiting | dobri-kiprov | Nov 30, 2023 | 40 |
| NCT06150833Primary Immunodeficiency Diseases | 3 | Not yet recruiting | Azidus Brasil | Sep 2028 | 50 |
| NCT06076642Primary Immunodeficiency Diseases · United States, Czechia, Denmark and more | 3 | Active, not recruiting | Takeda | May 16, 2028 | 53 |
| NCT06089122Primary Immunodeficiency Diseases | 3 | Not yet recruiting | Azidus Brasil | Jan 8, 2025 | 50 |
| NCT06015750Hypophosphatasia | 4 | Withdrawn | AstraZeneca | Mar 13, 2030 | 0 |
| NCT05755035Primary Immunodeficiency Diseases · United States, Czechia, Denmark and more | 3 | Completed | Takeda | Jan 20, 2026 | 65 |
| NCT05422365Purpura, Thrombocytopenic, Idiopathic · Ukraine | 3 | Completed | biopharma-plasma-llc | Dec 14, 2023 | 32 |
| NCT05177939Autoimmune Diseases of the Nervous System · Japan | 3 | UNKNOWN | Nihon Pharmaceutical | May 31, 2024 | 40 |
| NCT05059977Healthy Volunteers · United States | 1 | Completed | Takeda | Apr 12, 2022 | 24 |
| NCT04944979Primary Immunodeficiency Diseases · United States, Hungary, Italy and more | 3 | Active, not recruiting | Kedrion | Dec 2026 | 30 |
| NCT04643587Noncystic Fibrosis Bronchiectasis (NCFB) · Germany, United Kingdom | 1 | Completed | CSL | Mar 12, 2023 | 64 |
| NCT04640142Primary Immunodeficiency Diseases · United States, Germany, Hungary and more | 3 | Active, not recruiting | Octapharma | Nov 2026 | 50 |
| NCT04565015Primary Immunodeficiency Diseases · United States, Bosnia and Herzegovina, Serbia | 3 | Active, not recruiting | GC Biopharma | May 2026 | 24 |
| NCT04500067COVID-19 · Ukraine | 3 | Completed | biopharma-plasma-llc | Sep 15, 2020 | 76 |
| NCT04432324COVID-19 · Spain | 2 | Completed | Grifols | Mar 3, 2021 | 100 |
| NCT04346108Primary Immunodeficiency Diseases · Japan | 3 | Completed | Takeda | Dec 22, 2021 | 17 |
| NCT04044690Dermatomyositis · United States, Argentina, Belgium and more | 3 | Terminated | CSL | Dec 2, 2024 | 134 |
| NCT03961009Primary Immunodeficiency Diseases · United States | 3 | Completed | Kedrion | Dec 21, 2020 | 47 |
| NCT03351933Anti-Hepatitis A Antibody Levels in Heathy Subjects · United States | 4 | Completed | Grifols | Apr 27, 2018 | 28 |
| NCT03348618Pediatric acute-onset neuropsychiatric syndrome · United States | 4 | UNKNOWN | immunoe-research-centers | Nov 2019 | 21 |
| NCT03238079Primary Immunodeficiency Diseases · United States, Canada | 3 | Completed | evolve-biologics | Aug 25, 2020 | 63 |
| NCT03116347Primary Immunodeficiency Diseases · Czechia, Denmark, France and more | 4 | Completed | Takeda | Jan 15, 2021 | 42 |
| NCT02783482Immunologic Deficiency Syndromes · United States, Canada | 3 | Completed | GC Biopharma | Jul 2019 | 49 |
| NCT02638207Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy · Bulgaria, Canada, Czechia and more | 3 | Completed | Octapharma | Sep 5, 2019 | 142 |
| NCT02473965Myasthenia Gravis · United States, Belgium, Canada and more | 2 | Completed | Grifols | Feb 2019 | 60 |
| NCT02473952Myasthenia Gravis · United States, Belgium, Canada and more | 2 | Completed | Grifols | Jan 2018 | 62 |
| NCT02413580Myasthenia Gravis Exacerbations · Argentina, Belgium, Canada and more | 3 | Completed | Grifols | Apr 2018 | 49 |
| NCT02342184Guillain-Barre Syndrome · Japan | 3 | Completed | Japan Blood Products Organization | Sep 2015 | 21 |
| NCT02221271Guillain-Barre Syndrome · Japan | 3 | Completed | Nihon Pharmaceutical | Aug 2015 | 22 |
| NCT02199925Autistic Disorder · United States | 4 | UNKNOWN | isaac-melamed | Apr 2015 | 30 |
| NCT02184741Abortion, Habitual · Japan | 3 | Completed | Japan Blood Products Organization | May 2020 | 99 |
| NCT02176863Postpoliomyelitis Syndrome · United States, Canada, Czechia and more | 3 | Terminated | Grifols | Nov 24, 2022 | 191 |
| NCT02032095Kidney Failure, Chronic · Japan | 3 | Completed | Japan Blood Products Organization | Sep 2015 | 17 |
| NCT01985373Primary Immunodeficiency Diseases · Netherlands | 3 | Completed | Prothya Biosolutions | Mar 2015 | 23 |
| NCT01845584Neuromyelitis Optica · Japan | 2 | Completed | Nihon Pharmaceutical | Aug 2015 | 7 |
| NCT01827072Multifocal Motor Neuropathy · Japan | 3 | Completed | Nihon Pharmaceutical | Jun 2015 | 13 |
| NCT01824251Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Japan | 3 | Completed | Nihon Pharmaceutical | Sep 2015 | 49 |
| NCT01736579Alzheimer´s Disease · United States | 3 | Terminated | Takeda | Jun 4, 2013 | 6 |
| NCT01696500Stevens-Johnson Syndrome · Japan | 3 | Completed | Nihon Pharmaceutical | Jun 2014 | 10 |
| NCT01581593Primary Immunodeficiency Diseases · United States, Canada | 3 | Completed | Kedrion | Aug 27, 2014 | 45 |
| NCT01524887Alzheimer´s Disease · United States, Australia, Belgium and more | 3 | Terminated | Takeda | Jul 16, 2013 | 508 |
| NCT01465958Primary Immunodeficiency Diseases · United States | 4 | Completed | Grifols | Oct 2013 | 12 |
| NCT01461018Primary Immunodeficiency Diseases · Japan | 3 | Completed | CSL | Jul 2014 | 22 |
| NCT01458171Primary Immunodeficiency Diseases · Japan | 3 | Completed | CSL | Feb 2012 | 23 |
| NCT01412385Primary Immunodeficiency Diseases · Austria, Germany, Hungary and more | 3 | Completed | Takeda | May 13, 2014 | 55 |
| NCT01408550Pemphigoid, Bullous · Japan | 3 | Completed | Nihon Pharmaceutical | Sep 2013 | 56 |
| NCT01406470Immunologic Deficiency Syndromes · United States, Canada | 3 | Completed | GC Biopharma | Jul 2013 | 45 |
| NCT01349790Purpura, Thrombocytopenic, Idiopathic · Germany | 3 | Completed | Octapharma | Jul 2013 | 40 |
| NCT01313507Primary Immunodeficiency Diseases · United States | 3 | Completed | Octapharma | Sep 2012 | 21 |
| NCT01218438Primary Immunodeficiency Diseases · United States, Canada | 3 | Completed | Takeda | Mar 13, 2015 | 86 |
| NCT01225276Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 3 | Terminated | Octapharma | Oct 2012 | 2 |
How it is read
Names in the registry
- “NPB-01”, 7 entries
- “TAK-881”, 6 entries
- “IVIG”, 6 entries
- “Kedrion IVIG 10%”, 4 entries
- “GB-0998”, 4 entries
Codes read as this program: TAK881, GC5107, GB0998.
Conditions, from the studies’ own filings
- Primary Immunodeficiency Diseases, 24 studies
- Purpura, Thrombocytopenic, Idiopathic, 6 studies
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 5 studies
- Immunologic Deficiency Syndromes, 4 studies
- Myasthenia Gravis, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.